ReviewGastroenterology2019
Pathogenesis of and New Therapies for Hepatitis D.
Review in Gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Diagnostic Efficacy of Serological Antibody Detection Tests for Hepatitis Delta Virus: A Systematic Review and Meta-Analysis.Viruses · 2023Pooled it
- Underestimated Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis D Virus (HDV) Triple Infection Globally: Systematic Review and Meta-analysis.JMIR public health and surveillance · 2022Pooled it
- The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.Journal of hepatology · 2020Pooled it
- Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.Liver international : official journal of the International Association for the Study of the Liver · 2025Trial
- Article
- Hepatitis B virus and hepatitis D virus co-infection complicated by autoimmune hepatitis: Two case reports.World journal of clinical cases · 2025Article
- Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.Virology journal · 2025Review
- Proteins and peptides as antigen candidates for the immunodiagnosis of hepatitis D.Amino acids · 2025Review
- A comprehensive review of diagnostic approaches for hepatitis D.Frontiers in molecular biosciences · 2025Review
- Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses.Emerging microbes & infections · 2024Article
- Acacetin, a Natural Flavone with Potential in Improving Liver Disease Based on Its Anti-Inflammation, Anti-Cancer, Anti-Infection and Other Effects.Molecules (Basel, Switzerland) · 2024Review
- Role of viral hepatitis in pregnancy and its triggering mechanism.Journal of translational internal medicine · 2024Article
- Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in mice.PLoS pathogens · 2024Article
- Prospective study of hepatitis B and D epidemiology and risk factors in Romania: A 10-year update.World journal of hepatology · 2024Article
- Hepatitis B Vaccine: Four Decades on.Vaccines · 2024Review
- Prevalence of HDV infections in Poland based on the experience of a single center in Silesia and literature research.Clinical and experimental hepatology · 2024Article
- Prevalence of hepatitis D virus infection among patients with chronic hepatitis B infection in a tertiary care centre in Thailand.Scientific reports · 2023Article
- CRISPR/Cas13a-Assisted accurate and portable hepatitis D virus RNA detection.Emerging microbes & infections · 2023Article
- Performance of Hepatitis Delta Virus (HDV) RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta-analysis.Journal of clinical and translational hepatology · 2023Article
- Hepatitis D virus dual-infection among Chinese hepatitis B patient related to hepatitis B surface antigen, hepatitis B virus DNA and age.World journal of gastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Hepatitis delta virus (HDV) infection of humans was first reported in 1977, and now it is now estimated that 15-20 million people are infected worldwide. Infection with HDV can be an acute or chronic process that occurs only in patients with an hepatitis B virus infection. Chronic HDV infection commonly results in the most rapidly progressive form of viral hepatitis; it is the chronic viral infection that is most likely to lead to cirrhosis, and it is associated with an increased risk of hepatocellular carcinoma. HDV infection is the only chronic human hepatitis virus infection without a therapy approved by the US Food and Drug Administration. Peginterferon alfa is the only recommended therapy, but it produces unsatisfactory results. We review therapeutic agents in development, designed to disrupt the HDV life cycle, that might benefit patients with this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.